Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR720 in MAC pulmonary disease
NCT05496374Phase 2Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fobrepodacin in mycobacterium avium complex pulmonary disease (MAC-PD), sponsored by Spero Therapeutics. Started Dec 2022; status: completed.
02
Drugs
fobrepodacin
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT05496374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496374.